Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

MULTAQ 400 MG — DIN 02330989

DRONEDARONE (DRONEDARONE HYDROCHLORIDE) : 400 MG · SANOFI-AVENTIS CANADA INC · TABLET · wholesale supply in Canada

Health Canada status: MARKETED

What is MULTAQ?

MULTAQ 400 MG contains DRONEDARONE (DRONEDARONE HYDROCHLORIDE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02330989, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Sep-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is MULTAQ used for?

Treatment of paroxysmal or persistent atrial fibrillation (AF) in sinus rhythm or intended for cardioversion, to reduce risk of cardiovascular hospitalization due to AF.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Dronedarone cost around the world?

Dronedarone is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Italy publishes a prezzo al pubblico (classe A); United Kingdom publishes a hospital. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
Italyprezzo al pubblico (classe A)23EUR███.██
United Kingdomhospital22GBP███.██

5 pack listings across 4 brand entries and 2 price bases, refreshed 02 Sep 2026. Ranges span every Dronedarone pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

Is there a generic Dronedarone in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

2 holders have a Canadian DIN containing Dronedarone, across 2 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
SANOFI-AVENTIS CANADA INC11MULTAQSourceable in Canada
ASCEND LABORATORIES LTD10ASN-DRONEDARONENo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label400 MG
Dosage formTABLET
RouteORAL
Pack configuration (monograph)Bottles of 60, 180, and 500 tablets; boxes of 4 blisters (15 tablets per blister).
StorageStore at 15-30°C. (Note: General pharmaceutical standard, though specific text mentions "Store at" in section 11 which is not fully detailed in the snippet, section 6 mentions core/coating).

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceDronedarone
ATC codeC01BD07
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02330989
DIN (unpadded, as printed on some documents)2330989
Brand nameMULTAQ
Generic / active ingredientDRONEDARONE (DRONEDARONE HYDROCHLORIDE) : 400 MG
Market authorization holderSANOFI-AVENTIS CANADA INC
Health Canada schedulePrescription
ATC codeC01BD07
ATC anatomical main groupC — Cardiovascular system
ATC therapeutic subgroupC01BD
Current statusMARKETED
Status date28-Sep-2009
Original market date2009-10-14 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

How is it administered?

Recommended dose is 400 mg twice daily (one tablet with morning meal, one with evening meal). Stop Class I or III antiarrhythmics before starting.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

Permanent AF, history of/current heart failure, LV systolic dysfunction, 2nd/3rd degree AV block, bradycardia <50 bpm, severe hepatic impairment, pregnancy, lactation, strong CYP3A4 inhibitors.

Warnings and precautions

Risk of liver injury (including fatal failure), new/worsening heart failure, interstitial lung disease, and increased risk of death/stroke in permanent AF. Monitor ECG and renal function.

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
ASN-DRONEDARONE400 MGTABLETASCEND LABORATORIES LTDAPPROVED02514397

2 · Same class — other molecules in ATC C01BD

MoleculeCanadian brandsDINsMarketedSourceable
AmiodaroneAMIODARONE &middot; AMIODARONE FOR INJECTION 50MG/ML &middot; AMIODARONE HYDROCHLORIDE FOR INJECTION &middot; AMIODARONE HYDROCHLORIDE FOR INJECTION, USP &middot; +22 more3512Yes
DronedaroneASN-DRONEDARONE &middot; MULTAQ21Yes
IbutilideCORVERT11Yes
Bretylium TosilateBRETYLATE INJ 50MG/ML &middot; BRETYLIUM TOSYLATE 0.2% AND DEXTROSE 5% INJ &middot; BRETYLIUM TOSYLATE 0.4% AND DEXTROSE 5% INJ &middot; BRETYLIUM TOSYLATE INJ 50MG/ML &middot; +1 more50Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC C01B

ATC subgroupMoleculesDINsMarketed
C01BCFlecainide &middot; Propafenone3516
C01BBLidocaine &middot; Mexiletine &middot; Tocainide228
C01BADisopyramide &middot; Procainamide &middot; Quinidine441
C01BGVernakalant11

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for MULTAQ

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02330989. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.